FIELD: medicine.
SUBSTANCE: group of inventions is based on modulation of Hedgehog signalling transduction pathways. In more detail, the group of inventions refers to methods of treating Hedgehog related cancer. Particularly, the application describes methods of inhibition of abnormal growth conditions caused by such phenotypes, as loss of the Ptch function, dominant-negative intensification of the Hedgehog function, dominant-negative intensification of the Smoothened function or dominant-negative intensification of the Gli function consisting in administering a combination containing Smoothened inhibitors and Gli inhibitors or phosphatidylinositol-3-kinase (PI3K) inhibitors into a mammal.
EFFECT: group of inventions enables treating Hedgehog-related cancers effectively.
6 cl, 4 tbl, 2 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND COMPOSITIONS AS MODULATORS OF HEDGEHOG PATHWAY | 2007 |
|
RU2413718C2 |
| BIOMARKERS FOR THERAPY, BASED ON HEDGEHOG INHIBITOR | 2012 |
|
RU2602185C2 |
| CRYSTALLINE FORM OF 2-CHLORO-4-METHOXY-N-[4-(8-METHYL-IMIDAZO[1,2-a]PYRIDIN-2-YL)-PHENYL]-BENZAMIDE, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINAL AGENT | 2014 |
|
RU2569305C1 |
| BENZIMIDAZOLE AND IMIDAZO[4,5-c]PYRIDINE DERIVATIVES AS HEDGEHOG PATHWAY ANTAGONIST | 2010 |
|
RU2533825C2 |
| 2-ARYLIMIDAZO[1,2-b]PYRIDAZINE,2-PHENYLIMIDAZO[1,2-a]PYRIDINE AND 2-PHENYLIMIDAZO[1,2-a]PYRAZINE DERIVATIVES | 2011 |
|
RU2598385C2 |
| COMBINED THERAPY BASED ON CD20 ANTIBODY COMBINED WITH BCL-2 INHIBITOR AND MDM2 INHIBITOR | 2016 |
|
RU2727196C2 |
| AGENT FOR SENSORINEURAL HEARING LOSS TREATMENT (VERSIONS) | 2015 |
|
RU2614487C1 |
| COMPOUNDS AND COMPOSITIONS - HEDGEHOG SIGNALLING PATHWAY MODULATORS | 2007 |
|
RU2423354C2 |
| PHARMACEUTICAL COMBINATION COMPRISING INHIBITOR PHOSPHATYLENOSITOL 3-KINASES AND AROMATASE INHIBITOR | 2013 |
|
RU2651023C2 |
| CYCLOPAMINE ANALOGUES AND METHODS OF THEIR APPLICATION | 2005 |
|
RU2403256C2 |
